Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 4/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25090260 | 0.91 | NAMPT (0.36) | NAMPTCYP2D6 | |
| SCHEMBL25089997 | 0.90 | HRH3 (0.32) | HRH3CYP2D6 | |
| SCHEMBL25101607 | 0.89 | NAMPT (0.35) | NAMPTHRH3 | |
| SCHEMBL25090003 | 0.88 | DRD2 (0.33) | HRH3 | |
| SCHEMBL25089968 | 0.85 | NAMPT (0.35) | NAMPTHRH3 | |
| SCHEMBL24941792 | 0.85 | NAMPT (0.34) | NAMPTHRH3 | |
| SCHEMBL25089655 | 0.81 | NAMPT (0.47) | NAMPT | |
| SCHEMBL22306145 | 0.78 | HRH3 (0.35) | NAMPTHRH3CYP2D6 | |
| SCHEMBL26141946 | 0.77 | EPHX1 (0.32) | HRH3 | |
| SCHEMBL24941968 | 0.77 | KCNH2 (0.39) | HRH3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-02-29 | — | — | US | disclosed |
| US-20230331722-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-10-19 | — | — | US | disclosed |
| US-11767330-B2 | Citrate salt, pharmaceutical compositions, and methods of making and using the same | FOGHORN THERAPEUTICS INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230142883-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230065463-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331722-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | NAMPT 1153/4885HRH3 2014/4885CYP2D6 3897/4885 |
| US-20230142883-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | NAMPT 1153/4885HRH3 2014/4885CYP2D6 3897/4885 |
| US-11767330-B2 | Citrate salt, pharmaceutical compositions, and methods of making and using the same | CS, SMARCC2, SMARCC1 | NAMPT 2299/4885HRH3 2752/4885CYP2D6 2726/4885 |
| US-20230065463-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | NAMPT 1153/4885HRH3 2014/4885CYP2D6 3897/4885 |
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | NAMPT 1153/4885HRH3 2014/4885CYP2D6 3897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.